# Table of Contents

1. **Introduction** \hspace{5em} 1-5

2. **Review of Literature** \hspace{5em} 6-40
   - 2.1. Diabetes \hspace{5em} 6
   - 2.2. Bioactive compounds and diabetes \hspace{5em} 14
   - 2.3. Polymeric Drug delivery systems \hspace{5em} 23
   - 2.4. Biodegradable polymeric nanoparticles \hspace{5em} 25
   - 2.5. Nano-bioactive compounds for the treatment of type-2 diabetes \hspace{5em} 30
   - 2.6. Polymers used in the present study \hspace{5em} 32
   - 2.7. Bioactive compounds selected for evaluation \hspace{5em} 34

3. **Materials and Methods** \hspace{5em} 41-58
   - 3.1. Materials \hspace{5em} 41
   - 3.2. Animals \hspace{5em} 41
   - 3.3. Equipments \hspace{5em} 41
   - 3.4. Synthesis of polymeric nanoparticles for evaluation of anti-diabetic activity \hspace{5em} 42
   - 3.5. Synthesis of polymeric nanocapsules for evaluation of anti-diabetic activity \hspace{5em} 44
   - 3.6. Formation of combined nanoformulation \hspace{5em} 47
   - 3.7. Characterization of nanoformulations for evaluation of anti-diabetic activity \hspace{5em} 48
   - 3.8. *In vivo* anti-diabetic activity \hspace{5em} 51
   - 3.9. Statistical analysis \hspace{5em} 58

4. **Results and Discussion** \hspace{5em} 59-137
   - 4.1 Synthesis of polymeric nanoparticles for evaluation of anti-diabetic activity \hspace{5em} 59
   - 4.2 Synthesis of polymeric nanocapsules for evaluation of anti-diabetic activity \hspace{5em} 86
   - 4.3 Formation of combined nanoformulation for evaluation of anti-diabetic activity \hspace{5em} 120

5. **Summary and Conclusions** \hspace{5em} 138-141

6. **References** \hspace{5em} 142-171

7. **List of publications**